# A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

> **NCT02009878** · PHASE1,PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

## Interventions

- **DRUG:** tolvaptan

## Key facts

- **NCT ID:** NCT02009878
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02009878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02009878, "A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02009878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*